“We are delighted that both Susan Galbraith and Susan Searle have agreed to join Horizon's board of directors. Both have established highly successful careers in their chosen fields and also have proven leadership and advisory success. We believe each will be an invaluable asset to Horizon, and look forward to benefitting from their counsel,” says Darrin Disley, CEO of Horizon Discovery Group.
Monoclonal antibody developer Kymab (Cambridge, UK) has announced the appointments of Steve Arkinstall as CSO and Nigel Clark as vice president and head of business development. Arkinstall brings overs 25 years' experience across biopharmaceutical R&D, most recently as head of the Serono Research Institute in Boston as well as head of global technologies and external innovation at Merck Serono. As CSO he replaces founder Allan Bradley, who will serve as chief technology officer and continue as a member of Kymab's board of directors. Clark was previously chief business officer at Syntaxin, where he negotiated the sale of the company to Ipsen Pharma for $215 million. Prior to Syntaxin, he was head of business development at Vernalis.
This is a preview of subscription content, access via your institution
